Previous studies reported that silencing of GALNT2 could inhibit insulin-induced insulin receptor activation and Akt phosphorylation in hepatoma cells [46], whereas overexpression of GALNT2 in oral cancer cells could promote EGF-induced phosphorylation of EGFR and Akt [47]. The gene discussed is INS; the disease is hepatocellular carcinoma.